A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory

Updated 06/21/2024

Status Completed

Clinical Trial Summary

A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02349425
Study type	Interventional
Source	Afferent Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 9, 2015
Completion date	February 9, 2016

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03282591` - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough	Phase 2
	Completed	`NCT03407014` - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)	Phase 2
	Completed	`NCT02476890` - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)	Phase 2
	Recruiting	`NCT05599191` - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough	Phase 3
	Recruiting	`NCT03662269` - Indomethacin for Refractory Chronic Cough	Phase 3
	Recruiting	`NCT05962151` - Refractory Chronic Cough Improvement Via NAL ER (RIVER)	Phase 2
	Recruiting	`NCT05110144` - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough	Phase 2
	Active, not recruiting	`NCT04882943` - COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
	Enrolling by invitation	`NCT05733533` - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough	Phase 2
	Recruiting	`NCT05600777` - A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)	Phase 3
	Completed	`NCT05628740` - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175	Phase 1
	Not yet recruiting	`NCT06213363` - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough	Phase 1/Phase 2
	Completed	`NCT02412020` - Treatment of Refractory Chronic Cough With PA101	Phase 2
	Completed	`NCT04678206` - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough	Phase 2
	Completed	`NCT02612623` - An 8-Week Refractory Chronic Cough Study (MK-7264-021)	Phase 2
	Completed	`NCT02612610` - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)	Phase 2
	Completed	`NCT02397460` - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)	Phase 2
	Not yet recruiting	`NCT05265871` - ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough